The Gambia

in page functions
[French]
Gambia
Total population (2017) 2,120,418
Birth cohort (2017) 86,486
Surviving Infants (surviving to 1 year per year, 2017) 82,767
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 48/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 69/1000
World Bank Index, IDA (2015) 2.93
Gross Nation Income (per capita US$, 2014) 460
Co-financing group (2018) Initial self-financing
No. of districts/territories (2016) 7

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Gambia

Type of support

Approvals

2001-2022 (US$)
(28 Mar 2018)

Commitments

2001-2022 (US$)
(28 Mar 2018)

Disbursements

2000-2018 (US$)
(28 Mar 2018)

% Disbursed

(28 Mar 2018)
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Total $31,360,618 $38,103,659 $30,017,753
Cash Support (CASHSUPP) $195,000 $195,000 $195,000 100%
Health system strengthening (HSS 1) N/A
Health system strengthening (HSS 2) $3,284,459 $5,500,000 $1,574,306 48%
HepB mono (NVS) $455,977 $455,977 $455,977 100%
Hib mono (NVS) $410,021 $410,021 $410,021 100%
HPV (NVS) N/A
HPV Demo (NVS) $282,258 $282,258 $282,666 100%
HPV MAC (NVS) N/A
HPV MAC - Op costs (OPC) N/A
Immunisation services support (ISS) $671,640 $671,640 $671,640 100%
Injection Safety Devices (NVS) $72,000 $168,000 $89,927 125%
Injection safety support (INS) $101,184 $101,184 $101,184 100%
IPV (NVS) $203,279 $203,279 $134,279 66%
Measles (NVS) $139,910 $139,910 $139,774 100%
Measles-Rubella (NVS) $629,937 $629,937 $629,937 100%
Meningitis A (NVS) $75,500 $237,000 $82,556 109%
Meningitis A - campaign (NVS) $788,739 $788,739 $788,739 100%
Meningitis A - mini catch-up campaign (NVS) $223,500 $223,500 $234,867 105%
Meningitis A - mini catch-up op.costs (OPC) $198,424 $198,424 $198,424 100%
Meningitis A - operational costs (OPC) $727,500 $727,500 $727,500 100%
MR - Operational costs (OPC) $521,500 $521,500 $521,500 100%
Penta (NVS) $4,535,363 $4,974,363 $4,499,673 99%
Pneumo (NVS) $9,502,264 $12,330,264 $10,120,324 107%
Product Switch Grant (PSG) $29,999 $29,999 $29,999 100%
Rotavirus (NVS) $3,430,232 $4,433,232 $3,347,528 98%
Tetra DTP-Hib (NVS) $3,675,683 $3,675,683 $3,675,683 100%
Vaccine Introduction Grant (VIG) $1,206,249 $1,206,249 $1,106,249 92%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Gambia DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2016)

Grade of confidence


N/A
DTP3 - Official country estimates (2016) 95%
M:F sex ratio at birth (2017) 1.03
Household survey: DTP3 coverage for male (2012) 89.10%
Household survey: DTP3 coverage for female (2012) 86.20%
Household survey: Last DTP3 survey (2012) 88%
% districts achieving > 80% DTP3 coverage (2016) 100%
% districts achieving < 50% DTP3 coverage (2016) 0%
MCV WHO/UNICEF estimates (2016) 97%

Breakdown of support

Non-vaccine support Vaccine support
17% 83%
$5,125,802 $24,891,951

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Gambia

25 April 2017

Central African Republic, a mother and her two children.

Central African Republic: mother spreads word about meningitis A vaccine

Izimili Raude knows that her community must rely on vaccines, not miracles, to spare children from a deadly disease.

14 October 2016

Benin LOGIVAC

Africa takes second “step” toward strengthening supply chain management

New Strategic Training Executive Programme opens at Benin’s LOGIVAC+ Centre, 12 months after similar course offered in Rwanda

27 July 2016

First Sudanese child to receive Meningitis A vaccine as part of routine immunization.

Sudan: first to introduce life-saving meningitis A vaccine into routine immunization

Children in Sudan are set to become the first in the Meningitis belt to benefit from the introduction of Meningitis A vaccine into a routine immunization programme.

close icon

modal window here